Loading...
•
Mar 31, 2024
Ocugen Q1 2024 Earnings Report
Ocugen reported its financial results for Q1 2024 and provided a business update.
Key Takeaways
Ocugen reported a net loss of $11.924 million, or $0.05 per share, for the first quarter of 2024. The company's cash and cash equivalents totaled $26.4 million as of March 31, 2024. Ocugen is advancing its gene therapy programs, with OCU400 progressing to Phase 3 clinical trials.
OCU400 Phase 3 clinical trial is in progress.
OCU400 is on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets.
OCU410 is currently in Phase 1/2 stage of clinical development with active patient enrollment.
Completed renovating an existing facility into a current Good Manufacturing Practice (GMP) facility in accordance with the FDA's regulations.
Ocugen
Ocugen
Ocugen Revenue by Segment
Revenue by Segment
Collaborative Revenue
CapyFin.com Forward Guidance
Ocugen is focused on advancing its gene therapy programs and pursuing partnerships to support its entire pipeline.